CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

PT 3 is a benzamide-class, potent, and selective inhibitor of Histone Deacetylase 3 (HDAC3) with an IC50 of 245 nM. It crosses the blood-brain barrier and enhances learning and memory in novel object recognition models in mice.

CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

PT 3 is a benzamide-class, potent, and selective inhibitor of Histone Deacetylase 3 (HDAC3) with an IC50 of 245 nM. It crosses the blood-brain barrier and enhances learning and memory in novel object recognition models in mice.

PT 3 is a benzamide-class, potent, and selective inhibitor of Histone Deacetylase 3 (HDAC3) with an IC50 of 245 nM. It crosses the blood-brain barrier and enhances learning and memory in novel object recognition models in mice.

PT 3 is a benzamide-class, potent, and selective inhibitor of Histone Deacetylase 3 (HDAC3) with an IC50 of 245 nM. It crosses the blood-brain barrier and enhances learning and memory in novel object recognition models in mice.